Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jan 20, 2011
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies.
Virus removal by partitioning into different fractions during cold ethanol fractionation has been described by several authors, demonstrating that cold ethanol fractionation can provide significant contribution to virus removal, even in those cases where virus removal is limited and must be supported by additional measures for virus inactivation during further processing.
All
Publication
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1537-2995.2010.03003.x
Jan 20, 2011
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies.
Virus removal by partitioning into different fractions during cold ethanol fractionation has been described by several authors, demonstrating that cold ethanol fractionation can provide significant contribution to virus removal, even in those cases where virus removal is limited and must be supported by additional measures for virus inactivation during further processing.
All
Publication
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1537-2995.2010.03003.x
Mar 23, 2010
Human Parvovirus PARV4 and plasma protein therapies
Parvoviruses are small, non-enveloped DNA viruses that infect both vertebrate and invertebrate hosts. The human Parvovirus PARV4 has first been described in 2005 by Jones et al. For PARV4 no associated disease or specific symptoms have been observed.
All
PPTA statements
Mar 23, 2010
Human Parvovirus PARV4 and plasma protein therapies
Parvoviruses are small, non-enveloped DNA viruses that infect both vertebrate and invertebrate hosts. The human Parvovirus PARV4 has first been described in 2005 by Jones et al. For PARV4 no associated disease or specific symptoms have been observed.
All
PPTA statements
May 1, 2009
Source Plasma Donors and Donation
The Facts about Source Plasma Donors.
All
Fact sheets
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64529e2cea2349db307453d3_FS_Source_Plasma_Donors.pdf
May 1, 2009
Source Plasma Donors and Donation
The Facts about Source Plasma Donors.
All
Fact sheets
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64529e2cea2349db307453d3_FS_Source_Plasma_Donors.pdf
Apr 28, 2009
Statement on the Safety of Plasma Protein Therapies and Swine Influenza Virus
PPTA member companies are committed to providing safe and effective therapies and PPTA understands that patients who rely on these often life-saving therapies may have concerns about the possible transmission of Swine Influenza Virus through them in view of the recent outbreak in humans. Therapies produced by PPTA members remain safe and available.
All
PPTA statements
Apr 28, 2009
Statement on the Safety of Plasma Protein Therapies and Swine Influenza Virus
PPTA member companies are committed to providing safe and effective therapies and PPTA understands that patients who rely on these often life-saving therapies may have concerns about the possible transmission of Swine Influenza Virus through them in view of the recent outbreak in humans. Therapies produced by PPTA members remain safe and available.
All
PPTA statements
No results found